All Oncology News

Thierry André, MD, discusses findings from the phase 3 CheckMate 8HW trial of nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

Brandon G. Smaglo, MD, FACP, discusses upfront treatment considerations for patients with metastatic pancreatic cancer.

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

Erin K. Tagai, PhD, MPH, has received a grant from the Prevent Cancer Foundation to fund development of a ChatBot for patients receiving genetic testing results.

The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.

The FDA has granted orphan drug designation to bexmarilimab for myelodysplastic syndromes.

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Lisaftoclax plus azacitidine demonstrated clinical activity and was safe in higher-risk MDS.

The FDA has approved tislelizumab-jsgr plus chemotherapy for frontline use in adult patients with advanced esophageal squamous cell carcinoma and PD-L1 expression.

Quizartinib with 7+3 chemotherapy was safe and effective in patients with FLT3-ITD–negative AML, leading to the initiation of the phase 3 QuANTUM-Wild trial.

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.

5 WNY organizations received funding to advance cancer prevention, early detection, and patient support from Roswell Park Comprehensive Cancer Center.

The CHMP has recommended the approval of perioperative durvalumab plus neoadjuvant chemotherapy for patients with resectable NSCLC.

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

T-DXd improved overall survival in unresectable/metastatic HER2-positive gastric/GEJ adenocarcinoma after a trastuzumab-containing regimen.

Maurie Markman, MD, discusses the differences between prognostic vs predictive factors and their clinical utility in oncology practice.

Angela Jain, MD, discussed the current treatment paradigm in triple-negative breast cancer (TNBC), including currently investigated therapies, during TNBC Awareness Day.

Read a recap of the episodes of OncLive On Air that aired in February 2025.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

A retrospective study revealed that enfortumab vedotin did not produce excessive toxicity in older patients with urothelial carcinoma.

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

HRQOL results were evaluated in rural patients with bladder cancer and prostate cancer following ADT treatment and postoperative radiotherapy.

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Starting treatment within 60 days of initial evaluation significantly improves survival rates for patients with rectal cancer.

The CHMP has recommend the approval of subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma.

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

The CHMP has issued a positive opinion for linvoseltamab in relapsed/refractory multiple myeloma.